FOLH1 and metastatic neoplasm: Prostate-specific membrane antigen positron emission tomography (PSMA PET) was recently approved by the Food and Drug Administration1 and incorporated into the National Comprehensive Cancer Network (NCCN) guidelines.2 With evidence that PSMA PET has improved sensitivity in detecting nodal and metastatic disease compared with conventional imaging,3 wider use of PSMA PET will result in more patients found to have otherwise occult nodal or metastatic disease.